Cambridge, MA-based Forma Therapeutics has struck a collaboration deal with the U.S. unit of Tokyo-based drug powerhouse Eisai that is focused on discovering drugs against normally intractable disease targets, according to the companies. Eisai is paying Forma $20 million in upfront and committed fees over a three-year period, according to the companies. The deal gives Eisai non-exclusive access to Forma’s proprietary compound library and cell-based screening platforms to aid in Eisai’s discovery of new drugs for its own pipeline. Forma is eligible for potential milestone payments and royalties on products that Eisai might decide to develop as a result of the collaboration.

Comments | Reprints | Share:          

I’m extremely pleased to report that Xconomy’s headquarters in Cambridge are jam packed this week, since everybody flew in from our Seattle and San Diego offices for the inaugural XSITE—Xconomy Summit on Innovation, Technology, and Entrepreneurship—yesterday at Boston University. It’s a rare treat to have everybody together and, fortuitously, we’re also coming up on the second anniversary (this Saturday) of publishing Xconomy.com.

Today and tomorrow we’ll be taking a little time to celebrate that milestone and taking advantage of the surplus of colleagues (and working around the deficit of space) to work on making the site even better in the years to come. As always, we welcome the comments and suggestions of our readers—you can reach us at editors@xconomy.com or simply post in the comments below.

Our own posting will be light today and tomorrow, but we’ll be back Monday full force. Thanks to our incredible team for making Xconomy such a success and so damn fun to put together each day. Thanks to our underwriters, sponsors, and partners for two years of exceptional support (and in the case of Alexandria Real Estate Equities, for solving our aforementioned space problem). And thanks to all of you for reading, participating in our events, sharing your ideas and opinions, and helping us to build our network. We’re all looking forward to the next two years.

Comments | Reprints | Share: